Lilly stock trades near record territory as obesity and diabetes portfolio drives double digit growth

Eli Lilly and Company (ISIN US5324571083) is one of the largest US-based pharmaceutical manufacturers, and Lilly stock has been supported in recent years by strong demand for innovative therapies in diabetes and obesity. The company’s latest reported full year figures for fiscal 2024 showed total revenue of around $41.0 billion, marking a clear step up from earlier years and cementing Lilly’s position among the global drug majors. Investors have paid close attention to the way this revenue mix has shifted toward newer treatments, especially injectable incretin-based drugs for metabolic diseases.

The long term narrative behind Lilly stock is the transformation from a traditional diversified pharmaceutical group into a company whose growth is increasingly concentrated in very large, scalable franchises. In diabetes, Eli Lilly has worked for decades on insulin products and more recently on GLP-1 and GIP agonists that help patients manage blood sugar and, in some indications, weight. In obesity, launch momentum has come from the same class of incretin therapies, where clinical data suggest meaningful weight reduction for eligible patients. This has translated into a rapid ramp in prescriptions and, consequently, revenue. For investors, the core question in 2026 and beyond is how far these franchises can grow and how durable the competitive edge will be as rivals develop comparable agents.

Revenue growth above prior year

According to the company’s most recent annual reporting for fiscal 2024, Eli Lilly generated total revenue of about $41.0 billion, which represented a double digit percentage increase compared with the previous year’s approximate $34.0 billion. This means that revenue climbed by roughly $7.0 billion year on year, underscoring the scale at which Lilly’s portfolio has expanded. While exact reported percentages vary slightly depending on constant currency adjustments, the underlying message in the figures is that Lilly delivered high teens to low twenties growth at group level, driven by its new generation metabolic drugs along with continued performance in other key therapeutic areas.

Within that group revenue, diabetes and obesity therapies now account for a significant share. In the latest annual numbers, revenue attributed to such metabolic treatments was widely reported as being more than $10.0 billion, reflecting the rapid adoption by patients and prescribing physicians. Compared with earlier periods, where metabolic treatments contributed meaningfully less than $5.0 billion, this implies that Lilly effectively more than doubled its revenue base in that franchise over a span of roughly two fiscal years. The trend indicates that the company is not only capturing volume growth but also maintaining favorable pricing and reimbursement conditions in major markets.

Investors examining Lilly stock often drill down into segment-level comparisons, and the most recent figures highlight how intensive the shift has been. For example, if the metabolic franchise delivered around $10.0 billion in fiscal 2024 versus about $5.0 billion in fiscal 2022, that corresponds to an approximate 100% increase over two years. Even adjusting for currency and one-off factors, this scale of expansion is unusual for a large established pharmaceutical company and points to the exceptional demand profile of Lilly’s flagship treatments. It also implies that smaller franchises, while still relevant, are declining in relative contribution as the company’s growth story becomes more centered on diabetes and obesity.

Operating metrics and margin dynamics

Beyond revenue, investors focus closely on profitability metrics to gauge how sustainable the current growth trajectory may be. Eli Lilly’s latest reported full year results indicate that operating income increased alongside revenue in fiscal 2024, with an operating income figure in the region of $12.0 billion compared with around $9.0 billion in the prior year. This would translate into an improvement of roughly $3.0 billion year on year, indicating that the company has been able to scale its cost base efficiently as volumes rise. The ratio of operating income to total revenue suggests an operating margin in the high twenties percent range, which is consistent with other large research driven pharmaceutical companies but potentially benefits from the high value nature of Lilly’s leading products.

Net income and earnings per share also reflect this profitability dynamic. In fiscal 2024, net income attributable to Eli Lilly shareholders was widely reported as being near $10.0 billion, compared with roughly $6.0 billion in the prior year. This implies an increase in net earnings of about $4.0 billion, helping to drive growth in diluted earnings per share. On a per share basis, earnings have been reported in the range of $10.00 to $12.00 for the latest fiscal year, well above prior year levels that were closer to the mid single digit dollars per share. The gap between these figures gives investors a clear numerical sense of how strongly Lilly’s bottom line has leveraged its top line in the current product cycle.

Cash flow metrics reinforce the perception of a robust financial profile. Operating cash flow for fiscal 2024 has been indicated at around $13.0 billion, which would represent a substantial increase over figures in the region of $9.0 billion two years earlier. This expansion in cash generation provides Lilly with flexibility to invest in further research and development, expand manufacturing capacity for high demand drugs, pay dividends, and consider strategic acquisitions or partnerships. It also serves as a buffer against potential future pressure on pricing or reimbursement, as the company could choose to absorb some margin compression while maintaining essential investment programs.

Dividend payments form another important metric for long term holders of Lilly stock. The company has a long history of paying regular dividends and has typically increased its payout over time. In recent periods, the annual dividend per share has been reported in the rough range of $3.00 to $4.00, representing a steady uplift on prior years when the dividend was closer to $2.00 per share. While yield is kept relatively modest due to the strong share price performance, dividend growth provides a tangible signal that management is confident in the underlying cash flow strength and is willing to share a portion of that with shareholders.

Guidance and comparison with expectations

Forward looking guidance is critical for interpreting Lilly stock’s valuation. In the latest publicly communicated outlook, which covered fiscal 2025, the company indicated an expectation of continued double digit revenue growth, with guidance ranges pointing to total revenue somewhere between approximately $46.0 billion and $48.0 billion. Compared with the fiscal 2024 figure of around $41.0 billion, this guidance implies an expected year on year increase of roughly $5.0 billion to $7.0 billion. The midpoint of the range suggests growth in the low to mid teens percentage area, which investors tend to regard as aggressive but achievable given current demand trends for the company’s metabolic therapies.

On the earnings front, guidance ranges for adjusted earnings per share have been described as targeting levels above the recent historical baseline, with expectations in the ballpark of $13.00 to $15.00 per share for the upcoming fiscal year. When compared with the previously reported earnings per share figures of around $10.00 to $12.00 for fiscal 2024, this would represent expected growth of approximately 20% to 30% at the midpoint. Such a forecast underscores management’s confidence that strong product-level momentum can be translated into profitability even as the company invests in scaling and new research. It also provides a benchmark against which external analysts and the market can measure actual performance as quarterly results are released.

Consensus expectations from market analysts broadly align with these company indications, though detailed numbers can vary across houses. Many observers project Lilly’s revenue to continue growing at a double digit pace over the coming two to three years, driven by further uptake of diabetes and obesity medications as well as contributions from oncology and immunology pipelines. Earnings per share forecasts tend to be slightly more conservative than management guidance, reflecting assumptions around possible pricing pressure and competition, but they still imply high teens to low twenties annual growth. This convergence of internal guidance and external consensus offers investors a relatively coherent framework for thinking about valuation, with the understanding that any significant deviation in coming quarters could result in a reassessment of Lilly stock’s premium pricing.

Compared with major peers in the pharmaceutical and biotech space, Lilly’s growth profile stands out. Companies focused heavily on oncology or immunology often show mid single digit to low double digit growth, while Lilly’s reported and guided figures indicate a stronger trajectory linked to its metabolic franchise. For example, if a peer’s revenue increases from $50.0 billion to $54.0 billion year on year, that reflects an 8% growth rate, while Lilly’s move from roughly $34.0 billion to $41.0 billion corresponds to about 20% growth. This disparity explains part of the valuation gap observed in market data, where Lilly stock commands a higher multiple of earnings and sales than many peers. Investors effectively pay for the expectation that this higher growth rate can be maintained over several years.

Product focus on metabolic therapies

A core element of Lilly’s current business profile is its metabolic therapy portfolio, particularly injectable incretin drugs for diabetes and obesity. The flagship product in this field has been reported to generate several billion dollars in annual revenue, reflecting its adoption for type 2 diabetes treatment and, in certain indications, weight management. Recent data show that prescriptions have continued to ramp, with monthly volumes significantly above levels recorded a year earlier. This helps to explain why the product’s revenue may have grown from roughly $3.0 billion to $8.0 billion over a two year period, a dramatic expansion that few other large scale drugs achieve once they are beyond the initial launch phase.

The company’s strategy in metabolic therapies encompasses both expanding capacity to meet demand and exploring further indications. Manufacturing investments are designed to ensure that patients can access treatment in a timely manner, reducing supply constraints that could otherwise limit revenue. In parallel, Lilly is conducting clinical trials aimed at demonstrating efficacy in additional disease areas where weight and metabolic factors play a role. Each successful study not only broadens the product label but also increases the potential patient population, thereby offering new layers of growth on top of the existing revenue base.

Broader portfolio contributions from diabetes and obesity medications also influence how investors interpret Lilly stock. Where a traditional insulin portfolio may have delivered stable but modest growth, the newer incretin based drugs have a different profile, characterized by higher pricing power and rapid adoption. This mix shift has implications for margin, as gross margins on newer agents can be higher than legacy treatments. If a legacy insulin product generated $1.0 billion in revenue at a 60% gross margin, while a new incretin drug generated $8.0 billion at a 75% gross margin, the combined effect on group level profitability would be significant. These numbers illustrate why cash flow and earnings have grown faster than revenue alone might suggest.

Outside metabolic disease, Lilly’s portfolio includes oncology, immunology, and neuroscience treatments, which together provide diversification. While none of these segments currently match the revenue momentum of diabetes and obesity therapies, they contribute to base earnings and help smooth volatility. Some newer oncology products have reported year on year revenue growth in the range of 20% to 30%, albeit from a smaller base, suggesting that Lilly could have multiple meaningful drivers over time. This diversification matters to investors because it reduces the risk that any single franchise’s challenges would entirely derail the broader investment case.

Shares near highs and market capitalization

Lilly stock is listed on the New York Stock Exchange, where it trades under the ticker LLY. Over recent months, the share price has been reported near historical highs, with quotes in the region of $850.00 to $900.00 per share as of mid 2026. Compared with levels around $450.00 a year earlier, this implies an approximate 90% increase in the space of twelve months. This sizeable appreciation reflects both the company’s strong fundamental performance and the market’s willingness to assign a premium valuation multiple to the future cash flows expected from its leading therapies.

The company’s market capitalization has consequently risen sharply. Data from major market portals indicate that Eli Lilly’s equity value is now in the area of $800.0 billion to $900.0 billion, making it one of the most valuable pharmaceutical and healthcare companies globally. If the market capitalization stood near $450.0 billion a year earlier, the move to nearly twice that level highlights how strongly market perceptions have shifted in favor of Lilly’s growth profile. This is not solely a function of share count changes; rather, it primarily reflects the significant uplift in share price driven by investor demand.

Technical chart analyses often highlight that Lilly stock trades near its fifty two week high, with pullbacks typically met by renewed buying interest. A year ago, the fifty two week high might have been set near $500.00 per share, whereas the current fifty two week high is reported around the $900.00 mark. This implies that the band within which long term investors analyze support and resistance levels has shifted substantially higher. Such moves can attract new investor segments, including index funds aligned to large cap healthcare benchmarks and thematic funds focused on obesity and diabetes treatments.

For investors looking at valuation metrics, price to earnings and price to sales ratios for Lilly stock appear elevated relative to many large pharmaceutical peers. If the stock trades at around $900.00 with earnings per share of roughly $12.00, that corresponds to a price to earnings ratio of about 75, compared with ratios closer to 20 for some other global drug majors. Similarly, a market capitalization near $850.0 billion versus revenue of $41.0 billion implies a price to sales ratio of more than 20. These numbers indicate that the market is pricing in sustained high growth and profitability, alongside a relatively low perceived risk of major setbacks in the diabetes and obesity franchises.

Diabetes and obesity portfolio

The diabetes and obesity portfolio is central to Lilly’s growth story and helps explain why Lilly stock commands such a high valuation. The leading incretin based drug in this segment addresses both glycemic control and weight reduction, with clinical studies showing average weight loss figures significantly above those seen with older treatments. For patients with type 2 diabetes, improved glycemic control reduces the risk of complications such as cardiovascular disease and kidney impairment, which in turn supports better long term outcomes. For patients being treated primarily for obesity, the weight loss effect can lead to improvements in multiple metabolic parameters, including blood pressure and lipid profiles.

From a revenue standpoint, the diabetes and obesity portfolio has shifted from being a supportive element of Lilly’s business to a dominant driver. If the portfolio generated about $5.0 billion in revenue as recently as fiscal 2022 and now delivers around $10.0 billion in fiscal 2024, the doubling of revenue in only two years demonstrates how rapidly the new therapies have been adopted. It also suggests that underlying demand for effective obesity treatments is substantial and that payers are willing to reimburse these drugs given their potential to reduce long term healthcare costs linked to chronic disease management.

Manufacturing capacity and supply chain investments are critical to sustaining this momentum. Lilly has committed significant capital to expanding production facilities for its metabolic therapies, with reported capital expenditure in the high single digit billions of dollars range over recent years, a portion of which is dedicated specifically to diabetes and obesity treatments. If total capital expenditure grew from roughly $3.0 billion in fiscal 2022 to about $6.0 billion in fiscal 2024, this indicates a clear doubling of investment aimed at supporting future growth. Such figures are notable because they show that management is willing to reinvest a substantial portion of cash flow to ensure that demand can be met without interruption.

The company’s regulatory and market access strategy is another important pillar supporting the diabetes and obesity portfolio. Obtaining approvals from key regulators such as the US Food and Drug Administration and counterparts in Europe and Asia has allowed Lilly to commercialize its therapies across multiple major markets. While specific approval dates and labeling details vary, the broad pattern has been expansion into new countries and indications over the past three to five years. Each new approval effectively opens a new revenue stream, and the cumulative effect has been that metabolic therapies now represent a large and growing share of Lilly’s international business.

Lilly stock price context

From the perspective of current and prospective shareholders, the behavior of Lilly stock in public markets offers a real time indicator of sentiment. As noted, the share price has been trading near record levels, with recent quotes around $850.00 to $900.00 on the New York Stock Exchange. Over a multiyear horizon, this represents outstanding performance: if the shares were trading near $200.00 three years ago, the move to approximately $900.00 today would correspond to a more than fourfold increase. Such a trajectory places Lilly among the top performers in global large cap healthcare and reflects the market’s belief in the durability of its growth drivers.

Shorter term movements in the share price may be influenced by quarterly earnings releases, regulatory news, and broader macroeconomic factors. For example, a quarterly earnings report showing revenue modestly above consensus and earnings per share slightly below consensus could result in a brief pullback from recent highs as investors reassess expectations. Conversely, a report demonstrating revenue substantially ahead of expectations and stronger than anticipated margins could drive the stock to fresh highs. While individual days’ movements are difficult to predict, the longer term pattern of rising share price has so far been supported by fundamental progress.

In addition to absolute price levels, relative performance versus major stock indices provides context. Lilly stock is a constituent of the S&P 500, and recent multi year data indicate that it has significantly outperformed the index. If the S&P 500 has returned about 30% over three years, while Lilly stock has delivered a return of roughly 300%, the difference underscores the unique nature of Lilly’s growth profile. This outperformance is one reason why Lilly is a significant weight in sector specific exchange traded funds and why it features prominently in institutional portfolios focused on healthcare innovation.

Investors who consider buying or holding Lilly stock typically weigh this strong performance and premium valuation against potential risks. Key risk factors include the chance that competitors will launch broadly similar diabetes and obesity treatments, which could erode Lilly’s market share and pricing power, and the possibility of future regulatory or reimbursement changes that might constrain access to high cost therapies. Additionally, as with any large pharmaceutical company, Lilly faces the challenge of maintaining a robust pipeline of new products that can offset eventual patent expirations on current blockbusters. These considerations help explain why even a highly successful stock can be subject to volatility as new information emerges over time.